Evidence map›Paper›PMID 26581989›Full record

ArticleJournal of virology2016

Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Mary F Kearney, Ann Wiegand, Wei Shao, John M Coffin, John W Mellors, Michael Lederman, Rajesh T Gandhi, Brandon F Keele, Jonathan Z Li

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 152 citations in OpenAlex.

  1. Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks.Journal of acquired immune deficiency syndromes (1999) · 2026
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Broad activation of latent HIV-1 in vivo.Nature communications · 2016
    Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Proviruses in CD4Science translational medicine · 2025
    Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Mary F KearneyHIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA kearneym@ncifcrf.gov jli@bwh.harvard.edu.
Ann WiegandHIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA.
Wei ShaoLeidos Biomedical Research, Inc., Frederick National Laboratories for Cancer Research, Frederick, Maryland, USA.
John M CoffinDepartment of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, USA.
John W MellorsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Michael LedermanCase Western Reserve University, Cleveland, Ohio, USA.
Rajesh T GandhiMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Brandon F KeeleLeidos Biomedical Research, Inc., Frederick National Laboratories for Cancer Research, Frederick, Maryland, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA kearneym@ncifcrf.gov jli@bwh.harvard.edu.
National Cancer Institute · USBrigham and Women's Hospital · USCase Western Reserve University · USLeidos Biomedical Research Inc. (United States)Leidos (United States) · USMassachusetts General Hospital · USTufts University · USUniversity of Pittsburgh · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
Effects of Antiretroviral Therapy on Transcriptional Activity of HIV ProvirusesZIABC011697 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEARNEY, MARY · 2016 to 2024
$6.4M
Implications of HIV-1 Minority Variants for Virologic Failure and HIV ReservoirsK08AI100699 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, JONATHAN · 2012 to 2016
$682k
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI100699NIAID NIH HHS K08 AI100699NIAID NIH HHS U01 AI068636NIAID NIH HHS U01AI068636NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1AI106701
6 · The paper itself

Abstract

unlabelledUnderstanding the origin of HIV variants during viral rebound may provide insight into the composition of the HIV reservoir and has implications for the design of curative interventions. HIV single-genome sequences were obtained from 10 AIDS Clinical Trials Group participants who underwent analytic antiretroviral therapy (ART) interruption (ATI). Rebounding variants were compared with those in pre-ART plasma in all 10 participants and with on-ART peripheral blood mononuclear cell (PBMC)-associated DNA and RNA (CA-RNA) in 7/10 participants. The highest viral diversities were found in the DNA and CA-RNA populations. In 3 of 7 participants, we detected multiple, identical DNA and CA-RNA sequences during suppression on ART that exactly matched plasma HIV sequences. Hypermutated DNA and CA-RNA were detected in four participants, contributing to diversities in these compartments that were higher than in the pre-ART and post-ATI plasma. Shifts in the viral rebound populations could be detected in some participants over the 2- to 3-month observation period. These findings suggest that a source of initial rebound viremia could be populations of infected cells that clonally expanded prior to and/or during ART, some of which were already expressing HIV RNA before treatment was interrupted. These clonally expanding populations of HIV-infected cells may represent an important target for strategies aimed at achieving reservoir reduction and sustained virologic remission. IMPORTANCE: Antiretroviral therapy alone cannot eradicate the HIV reservoir, and viral rebound is generally rapid after treatment interruption. It has been suggested that clonal expansion of HIV-infected cells is an important mechanism of HIV reservoir persistence, but the contribution of these clonally proliferating cells to the rebounding virus is unknown. We report a study of AIDS Clinical Trials Group participants who underwent treatment interruption and compared rebounding plasma virus with that found within cells prior to treatment interruption. We found several incidences in which plasma HIV variants exactly matched that of multiple proviral DNA copies from infected blood cells sampled before treatment interruption. In addition, we found that these cells were not dormant but were generating unspliced RNA transcripts before treatment was interrupted. Identification of the HIV reservoir and determining its mechanisms for persistence may aid in the development of strategies toward a cure for HIV. (This study was presented in part at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 23 to 26 2015.).

Indexed as

Genetic VariationTranscription, GeneticAnti-Retroviral AgentsFemaleHIV InfectionsHumansMalePlasmaProvirusesAnti-Retroviral Agents

Identifiers

PMID26581989
PMCPMC4719635
OpenAlexW2284414405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.